A pipeline built on the right Patient × Target × Modality fit
Oncology R&D is unforgiving. Every program we advance is designed to reduce risk where it matters most: before the clinic.
Grounded in human tumor biology, each asset in our pipeline is shaped by a clear patient hypothesis - so target rationale, modality fit, and patient stratification align from the start.
Our programsIndivumed pipeline of biologics and small molecules
Starting in colorectal cancer - a high-impact disease where treatment options remain critically limited - and extending across other solid tumors like NSCLC or breast, our assets are built for evaluation, partnering, and progression.
- Phase
- Hit to Lead
- Type
-
Surfaceome
- Target Description
-
IN-2501 is a tumor-selective ion transporter in MSS colorectal cancer, addressable by ADC or functional antibody to drive targeted killing or disrupt oncogenic signaling. It fuels proliferation, EMT, and metastatic spread, with expression concentrated in metastatic MSS CRC and enriched in CMS2 and CMS4 subgroups.
Therapeutic Opportunity: MSS CRC remains refractory, and IN-2501 offers a biomarker-defined entry point with two mechanistically independent modalities. Independently published preclinical studies document anti-tumor activity for both. No competitive antibody programs are publicly disclosed.
- Phase
- Hit to Lead
- Type
-
Surfaceome
- Target Description
-
IN-2503 is a tumor-selective cell-surface anchor in MSS colorectal cancer, addressable by blocking antibody, ADC, or bispecific to drive targeted killing or immune cell recruitment. It acts as a dual-function driver: enzymatic survival signaling sustains a stem-cell-like program, while microenvironment interactions and oncogenic signaling facilitate metastasis and immune exclusion.
Therapeutic Opportunity: Immune exclusion is a key reason MSS CRC remains refractory to immunotherapy. Inhibition of IN-2503 restores immune infiltration and resensitizes tumors, positioning it as a biomarker-driven, first-in-class opportunity for next-generation combinations. No competitive antibody programs are publicly disclosed.
- Phase
- Target ID & Validation
- Group Size
-
14 targets, >50 epitopes
- Target Description
-
The Group of IN-2504 to IN-2517 is a pool of 14 biologic targets in colorectal cancer, selected for tumor-versus-normal differential expression, accessible extracellular architectures, and credible disease biology. Each target is enriched in clinically relevant CRC subgroups, including metastatic subsets, genomic markers, and consensuous molecular subtypes (CMS) classes. More than 50 epitopes across the set span multiple membrane architectures and functional classes, supporting antibody-based and targeted modality options with room for differentiated positioning.
With multiple monoclonal antibodies per epitope in hand, these targets are now in late-stage validation, where patient tissues and patient-derived cellular models resolve responding subgroups, confirm modality fit, and triage candidates for lead development.
- Phase
- Target ID & Validation
- Group Size
-
10 targets, >40 epitopes
- Target Description
-
The Group of IN-2518 to IN-2527 is a pool of 10 biologic targets in colorectal cancer, selected under the same criteria as IN-2504 to IN-2517. More than 40 epitopes across the set span a broad range of membrane architectures and functional classes, opening antibody-based, ADC, and immune-engaging modality options.
These targets are now in early-stage validation, where Indivumed's platform confirms expression and surface accessibility in patient-derived cellular models and guides antibody generation and modality selection.
)
- Phase
- Hit to Lead
- Target Description
-
Essential in the development and progression of various cancers through regulation of gene expression and cellular behavior, the target is a member of the RNA-helicase family and highly relevant for metastatic CRC.
Do you want to learn more?
Get in touch if you are interested in details of our current and future pipeline, ongoing development programs, or additional indications. We can address CRC, NSCLC, and other solid tumors. Looking forward to discuss a potential collaboration.
Our Pipeline Looking for assets that survive the clinic?
We don't just deliver targets – we deliver de-risked development packages.
What makes our assets different starts with the data behind them. Standardized tumor tissue produces comprehensive molecular data, paired with deep clinical insights from the same patient, all feeding our AI-driven analytics. This gives us target confidence that generic datasets can't match. Validation in patient-derived cellular models confirms the right modality fit before major capital is committed.
By defining patient selection criteria early, we compress timelines and reduce the risk of late-stage failure. Our partners can move from target to IND-enabling studies with translational clarity others can't provide.
)
“Our R&D approach brings novel insights through our unique starting point. Carefully collected and curated patient samples are excellent representations of the characteristic features of the disease, making the difference in target discovery and lead generation toward innovative and successful therapeutics.”